Literature DB >> 35484418

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.

Josep M Llovet1,2,3, Roser Pinyol4, Robin K Kelley5, Anthony El-Khoueiry6, Helen L Reeves7,8, Xin Wei Wang9,10, Gregory J Gores11, Augusto Villanueva12.   

Abstract

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers. The poor outcome associated with HCC is dramatically changing due to the advent of effective systemic therapies. Here we discuss the molecular pathogenesis of HCC, molecular classes and determinants of heterogeneity. In addition, effective single-agent and combination systemic therapies involving immunotherapies as standard of care are analyzed. Finally, we propose a flowchart of sequential therapies, explore mechanisms of resistance and address the need for predictive biomarkers.
© 2022. Springer Nature America, Inc.

Entities:  

Mesh：

Year:  2022        PMID： 35484418      PMCID： PMC9060366          DOI： 10.1038/s43018-022-00357-2

Source DB:  PubMed          Journal:  Nat Cancer        ISSN： 2662-1347


  164 in total

Review 1.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

2.  Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Authors:  F Michael Yakes; Jason Chen; Jenny Tan; Kyoko Yamaguchi; Yongchang Shi; Peiwen Yu; Fawn Qian; Felix Chu; Frauke Bentzien; Belinda Cancilla; Jessica Orf; Andrew You; A Douglas Laird; Stefan Engst; Lillian Lee; Justin Lesch; Yu-Chien Chou; Alison H Joly
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

Review 3.  Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Authors:  Josep M Llovet; Virginia Hernandez-Gea
Journal:  Clin Cancer Res       Date:  2014-03-03       Impact factor: 12.531

4.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

5.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

6.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Andrew X Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2019-01-18       Impact factor: 41.316

Review 7.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

8.  ZNRF3 and RNF43 cooperate to safeguard metabolic liver zonation and hepatocyte proliferation.

Authors:  Tianliang Sun; Stefano Annunziato; Sebastian Bergling; Caibin Sheng; Vanessa Orsini; Pascal Forcella; Monika Pikiolek; Venkatesh Kancherla; Sjoerd Holwerda; Dilek Imanci; Fabian Wu; Ludivine Challet Meylan; Lea F Puehringer; Annick Waldt; Mevion Oertli; Sven Schuierer; Luigi M Terracciano; Stefan Reinker; Heinz Ruffner; Tewis Bouwmeester; Andreas W Sailer; Elizabeth George; Guglielmo Roma; Antoine de Weck; Salvatore Piscuoglio; Felix Lohmann; Ulrike Naumann; Prisca Liberali; Feng Cong; Jan S Tchorz
Journal:  Cell Stem Cell       Date:  2021-06-14       Impact factor: 24.633

9.  A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.

Authors:  L Kadalayil; R Benini; L Pallan; J O'Beirne; L Marelli; D Yu; A Hackshaw; R Fox; P Johnson; A K Burroughs; D H Palmer; T Meyer
Journal:  Ann Oncol       Date:  2013-07-14       Impact factor: 32.976

Review 10.  Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials.

Authors:  Philippe Rochigneux; Brice Chanez; Bernadette De Rauglaudre; Emmanuel Mitry; Christian Chabannon; Marine Gilabert
Journal:  Cancers (Basel)       Date:  2021-01-13       Impact factor: 6.639
View more
  5 in total

Review 1.  The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity.

Authors:  Stavros P Papadakos; Nikolaos Dedes; Elias Kouroumalis; Stamatios Theocharis
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

2.  Hepatocellular carcinoma mutation landscape and its differences between Asians and Whites.

Authors:  Xingte Chen; Qiao Ke; Lei Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

Review 3.  Etiology, Pathogenesis, Diagnosis, and Practical Implications of Hepatocellular Neoplasms.

Authors:  Prodromos Hytiroglou; Paulette Bioulac-Sage; Neil D Theise; Christine Sempoux
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

4.  HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma.

Authors:  Chiyumi Oda; Kenya Kamimura; Osamu Shibata; Shinichi Morita; Yuto Tanaka; Toru Setsu; Hiroyuki Abe; Takeshi Yokoo; Akira Sakamaki; Hiroteru Kamimura; Satoshi Kofuji; Toshifumi Wakai; Hiroshi Nishina; Shuji Terai
Journal:  Biochem Biophys Rep       Date:  2022-09-20

5.  Prognostic Value of an Integrin-Based Signature in Hepatocellular Carcinoma and the Identification of Immunological Role of LIMS2.

Authors:  Fengning Ye; Hao Le; Fan He; Hao Tu; Dengfa Peng; Sini Ruan
Journal:  Dis Markers       Date:  2022-09-29       Impact factor: 3.464
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.